| Literature DB >> 35455725 |
Roi Suárez-Gil1, Emilio Casariego-Vales1, Rosa Blanco-López2, Fernando Santos-Guerra3, Cristina Pedrosa-Fraga1, Álvaro Fernández-Rial1, Iria Íñiguez-Vázquez1, María Mar Abad-García2, Mercedes Bal-Alvaredo1.
Abstract
AIM: This work aims to evaluate the safety and utility of an at-home telemedicine with telemonitoring program for discharged COVID-19 patients.Entities:
Keywords: COVID-19; hospital discharge; telemedicine
Year: 2022 PMID: 35455725 PMCID: PMC9029667 DOI: 10.3390/jpm12040609
Source DB: PubMed Journal: J Pers Med ISSN: 2075-4426
Monitoring quality criteria.
| Telemedicine protocol quality criteria: Monitoring was appropriately complied with if: At least 90% of the planned monitoring instances or contacts were conducted as scheduled. Fewer than three consecutive monitoring instances were not conducted. After not conducting one of the planned monitoring instances, the patient responded to a telephone call from the personnel and justified the delay. Monitoring complied with inconsistently, but clinically useful if: At least 80% of the planned monitoring instances or contacts were conducted as scheduled. Fewer than three consecutive monitoring instances were not conducted. After not conducting one of the planned monitoring instances, the patient responded to a telephone call from the personnel and justified the delay. Monitoring not appropriately complied with and not clinically useful if: Less than 80% of the planned monitoring instances or contacts were conducted as scheduled. Three or more consecutive monitoring instances were not conducted. After not conducting one of the planned monitoring instances, the patient did not respond to a telephone call, it was noted that he or she did not comply with the rules (for example, not remaining isolated), or he or she did not justify the delay. |
Figure 1Flowchart of readmitted discharged patients in the autonomous community of Galicia.
Characteristics of patients discharged from ASLAM hospitals.
|
| % | ||
|---|---|---|---|
|
| 738 | ||
| Men | 371 | 50.2% | |
| Mean age | 59.8 (SD 15.8) | ||
| Age groups | |||
| <18 | 4 | 0.5% | |
| 18–40 | 62 | 8.4% | |
| 41–50 | 55 | 7.5% | |
| 51–60 | 104 | 14.1% | |
| 61–70 | 147 | 19.9% | |
| 71–80 | 159 | 21.5% | |
| 81–90 | 165 | 22.3% | |
| >90 | 43 | 5.8% | |
| HTA | 415 | 56.15% | |
| Diabetes mellitus | 176 | 23.81% | |
| Obesity | 134 | 18.13% | |
| Arrhythmia | 72 | 9.74% | |
| Immunosuppression | 52 | 7.03% | |
| Non-hematologic neoplasm | 45 | 6.08% | |
| Ischemic heart disease | 38 | 5.14% | |
| COPD | 38 | 5.14% | |
| Heart failure | 28 | 3.78% | |
Evolution of discharges from ASLAM and the rest of Galicia.
| Galicia | ASLAM |
| ||
|---|---|---|---|---|
| ( | ( | |||
| Length of previous hospital stay (days) | 12.01 | 10.1 | <0.0001 | |
| (SD 12.14) | (SD 10.9) | |||
| Readmission | 705 | 50 | 0.05 | |
| (8.96%) | (6.8%) | |||
| Time until second hospitalization (days) | 17.6 | 18.2 | NS | |
| (SD 11.7) | (SD 9.9) | |||
| Length of second hospitalization (days) | 10.8 | 8.5 | 0.04 | |
| (SD 10.5) | (SD 7.5) | |||
| Mortality in second hospitalization | 123 | 11 | NS | |
| (17.4%) | (23%) | |||
| Emergency department visits | ||||
| 10 days | 733 | 82 | NS | |
| 30 days | 1242 | 126 | NS | |
| 90 days | 1633 | 169 | ||
| Death at 90 days | 404 | 44 | NS | |
| (5.2%) | (6%) | |||
| Death due to COVID-19 | 196 | 9 | 0.02 | |
| (2.5%) | (1.2%) | |||
Characteristics of patients discharged in ASLAM.
| Telemonitoring |
| |||
|---|---|---|---|---|
| YES | NO | |||
| n | 475 | 76 | ||
| Sex | 247 (52%) | 39 (51.3%) | ||
| Mean age | 66.5 (SD 16.1) | 70.8 (SD 16,7) | 0.03 | |
| Age groups | ||||
| 18–40 | 36 (7.6%) | 5 (6.6%) | ||
| 41–50 | 44 (9.3%) | 6 (7.9%) | ||
| 51–60 | 83 (17.5%) | 8 (10.5%) | ||
| 61–70 | 109 (22.9%) | 12 (15.8%) | ||
| 71–80 | 93 (19.6%) | 20 (26.3%) | ||
| 81–90 | 94 (19.8%) | 20 (26.3%) | ||
| >90 | 16 (3.4%) | 5 (6.6%) | ||
| HT | 264 (55.6%) | 6 (7.9%) | ||
| Diabetes mellitus | 116 (24.4%) | 21 (27.6%) | ||
| Obesity | 86 (18.1%) | 15 (19.7%) | ||
| Arrhythmia | 43 (9.1%) | 8 (10.5%) | ||
| Immunosuppression | 31 (6.5%) | 6 (7.9%) | ||
| Non-hematologic neoplasm | 26 (5.5%) | 5 (6.6%) | ||
| Ischemic heart disease | 24 (5.1%) | 4 (5.3%) | ||
| COPD | 21 (4.4%) | 5 (6.6%) | ||
| Heart failure | 19 (4%) | 3 (3.9%) | ||
| Death at 90 days | 0 | 2 (2.6%) | 0.001 | |
| Readmission | 9 (1.9%) | 5 (6.6%) | 0.01 | |